Respiratory syncytial virus in adults with comorbidities: an update on epidemiology, vaccines, and treatments.
RSV
RSV treatment
RSV vaccine
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
25
05
2023
revised:
19
08
2023
accepted:
30
08
2023
medline:
29
11
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) is widely known as a frequent cause of respiratory distress among adults, particularly in older people. Recent years have witnessed several improvements in respiratory virus detection, leading to more questions about therapeutic management strategies. This narrative review focuses on the RSV burden in older people and adults with risk factors and provides an update on the main recent developments regarding managing this infection. A comprehensive PubMed search was conducted till August 2023 to identify studies on RSV among the adult population. We included observational studies, RCTs on vaccines, and different therapies. This review should give clinicians an overview of RSV epidemiology and burden among older people and adults with pre-existing risk factors, the most recent randomized clinical trials on RSV vaccines, and the existing data on the different therapeutics existing and under development. There is a growing body of evidence on RSV burden in adults. The landscape of preventive and curative treatments is quickly evolving.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory syncytial virus (RSV) is widely known as a frequent cause of respiratory distress among adults, particularly in older people. Recent years have witnessed several improvements in respiratory virus detection, leading to more questions about therapeutic management strategies.
OBJECTIVES
OBJECTIVE
This narrative review focuses on the RSV burden in older people and adults with risk factors and provides an update on the main recent developments regarding managing this infection.
SOURCES
METHODS
A comprehensive PubMed search was conducted till August 2023 to identify studies on RSV among the adult population. We included observational studies, RCTs on vaccines, and different therapies.
CONTENT
BACKGROUND
This review should give clinicians an overview of RSV epidemiology and burden among older people and adults with pre-existing risk factors, the most recent randomized clinical trials on RSV vaccines, and the existing data on the different therapeutics existing and under development.
IMPLICATIONS
CONCLUSIONS
There is a growing body of evidence on RSV burden in adults. The landscape of preventive and curative treatments is quickly evolving.
Identifiants
pubmed: 37666450
pii: S1198-743X(23)00412-3
doi: 10.1016/j.cmi.2023.08.028
pii:
doi:
Substances chimiques
Respiratory Syncytial Virus Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1538-1550Informations de copyright
Copyright © 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.